Loading clinical trials...
Loading clinical trials...
Drug-eluting Beads Transarterial Chemoembolization Combined With Apatinib and PD-1 Antibody for the Treatment of Intrahepatic Cholangiocarcinoma That Has Progressed After Standard First-line Chemotherapy
Conditions
Interventions
DEB-TACE combined with apatinib and PD-1 antibody
Locations
1
China
Sichuan Cancer Hospital and Research Institute
Chengdu, Sichuan, China
Start Date
July 1, 2024
Primary Completion Date
April 30, 2025
Completion Date
April 30, 2026
Last Updated
June 25, 2024
NCT06971991
NCT07417397
NCT06313203
NCT07337850
NCT06925516
NCT06406816
Lead Sponsor
Sichuan Cancer Hospital and Research Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions